Submit Manuscript  

Article Details


Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS)

[ Vol. 19 , Issue. 1 ]

Author(s):

Nicolás R. Robles *, Rosa D. Campillejo, Julian Valladares, Elena G. de Vinuesa, Juan Villa and Guillermo Gervasini   Pages 93 - 97 ( 5 )

Abstract:


Background and Aims: Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the short-term effects of sacubitril- valsartan on the anemia of CRS.

Methods: The study group comprised 39 patients with HFrEF, who were followed-up for three months. The study is a retrospective analysis of clinical data. Data of 3 months’ and baseline visits were recorded including plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin, pro-BNP, and albuminuria.

Results: In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101 ± 62 mg/day and 126 ± 59 mg/day at end. Mean hemoglobin increased from 12.2 ± 1.1 g/dl at baseline to 12.9 ± 1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI, 47.9-78.5%) at baseline and 38.4 (95%CI, 23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71 ± 1.0 to 2.48 ± 1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline 4.94 ± 0.60, three months visit 4.94 ± 0.61 mmol/l, p = 0.998).

Conclusion: Sacubitril-valsartan improves anemia in CRS patients. An improvement in serum cystatin levels was observed. Few untoward effects were detected. These findings should be confirmed in wider clinical trials.

Keywords:

Anemia, cardio-renal syndrome, chronic kidney disease, cystatin C, heart failure, sacubitril-valsartan.

Affiliation:

Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Department of Nephrology, Hospital Universitario de Badajoz, Badajoz, Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz

Graphical Abstract:



Read Full-Text article